<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="91">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369212</url>
  </required_header>
  <id_info>
    <org_study_id>DK082864 HBRN Immune Active</org_study_id>
    <nct_id>NCT01369212</nct_id>
  </id_info>
  <brief_title>Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B</brief_title>
  <acronym>HBRN</acronym>
  <official_title>Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the efficacy of peginterferon plus tenofovir for 24 weeks
      followed by monotherapy with tenofovir for a further 3.5 years to the efficacy of tenofovir
      alone given for 4 years in patients with chronic hepatitis B. The primary measure of outcome
      will be HBsAg loss in serum at 48 weeks after stopping all antiviral therapy (sustained
      off-treatment response).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the long-term efficacy of treatment with
      combination therapy with peginterferon plus tenofovir versus tenofovir monotherapy in the
      treatment of chronic hepatitis B.

      This is a randomized (1:1) parallel group design trial comparing (i) Tenofovir DF 300 mg
      daily for 192 weeks (4 years) and (ii) peginterferon alfa-2a 180 µg weekly for 24 weeks plus
      Tenofovir DF 300 mg daily for 192 weeks (4 years). Enrolled participants will be stratified
      by HBeAg status (positive/negative), genotype (A vs. all others) and cirrhosis (present vs.
      absent). After 192 weeks of treatment, participants meeting criteria for treatment
      discontinuation will stop treatment and be followed for 48 weeks (total duration of
      treatment and follow up is 240 weeks). Emtricitabine/tenofovir coformulated as Truvada,
      approved for treatment of HIV but not for treatment of HBV infection, will be offered to
      patients with primary nonresponse, partial virological response or confirmed virologic
      breakthrough.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hepatitis B surface antigen (HBsAg) loss</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative HBsAg loss</measure>
    <time_frame>Week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative HBsAg loss</measure>
    <time_frame>Week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 240 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 240 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B e antigen (HBeAg) loss</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B e antigen (HBeAg) loss</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of Alanine Transaminase(ALT) levels</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
    <description>males ≤30 U/L, females ≤20 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of Alanine Transaminase(ALT) levels</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
    <description>males ≤30 U/L, females ≤20 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of Alanine Transaminase(ALT) levels</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
    <description>males ≤30 U/L, females ≤20 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;1000 IU/mL</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;1000 IU/mL</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;1000 IU/mL</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</measure>
    <time_frame>week 228</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA &lt;20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</measure>
    <time_frame>week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of detectable antiviral drug-resistance HBV mutations</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained HBV DNA &lt;1000 IU/mL</measure>
    <time_frame>week 192</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative HBsAg loss</measure>
    <time_frame>Week 240</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 192 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon-alfa 2a and tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>300 mg daily for 192 weeks (4 years)</description>
    <arm_group_label>Tenofovir</arm_group_label>
    <other_name>Hepatitis B</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon-alfa 2a and tenofovir</intervention_name>
    <description>A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).</description>
    <arm_group_label>Peginterferon-alfa 2a and tenofovir</arm_group_label>
    <other_name>Hepatitis B</other_name>
    <other_name>PEGASYS</other_name>
    <other_name>Viread</other_name>
    <other_name>tenofovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant is enrolled in the HBRN Cohort Study (NCT01263587) or completed the
             necessary components of the cohort baseline evaluation by the end of the baseline
             visit for this study

          -  18 years or older

          -  Chronic hepatitis B infection as evidenced by at least one of the following:

               1. HBsAg positive result within 8 weeks prior to randomization and another time at
                  least 24 weeks prior to randomization with no HBsAg negative result in between.

               2. HBsAg positive within 8 weeks prior to randomization and HBV DNA ≥1000 IU/mL on
                  2 occasions at least 24 weeks apart (can include result from screening visit
                  within 8 weeks of randomization)

          -  Hepatitis B e antigen positive or negative

          -  Serum HBV DNA ≥1000 IU/mL on 2 occasions at least 4 weeks apart within the 32 weeks
             prior to randomization (can include result from screening visit within 8 weeks of
             randomization)

          -  At least 2 elevated serum ALT levels (&gt; 30 U/L for males, &gt;20 U/L for females) 4
             weeks apart, and no more than 32 weeks apart, with the second being within 8 weeks of
             randomization

          -  Compensated liver disease

          -  No evidence of HCC

          -  Liver biopsy done that shows findings consistent with chronic hepatitis B with
             histology activity index (HAI) ≥3 (necroinflammatory component only) or Ishak
             fibrosis score ≥1 or both, as assessed by the local study pathologist on review of a
             liver biopsy done within 144 weeks of randomization

          -  Females of child bearing potential must agree to use an adequate method of
             contraception throughout the study and must have a negative pregnancy test
             immediately prior to the start of treatment

        Exclusion criteria:

          -  Serum ALT ≥450 U/L for males and ≥300 U/L for females

          -  Treatment with interferon or nucleos(t)ide analogues for hepatitis B within 48 weeks
             of randomization

          -  More than 48 weeks of therapy with nucleos(t)ide analogues for hepatitis B at any
             time in the past

          -  History of hepatic decompensation including but not limited to ascites, variceal
             bleeding, or hepatic encephalopathy

          -  Known allergy or intolerance to any of the study medications

          -  Females who are pregnant or breastfeeding

          -  Previous organ transplantation including engrafted bone marrow transplant

          -  Any other concomitant liver disease, including hemochromatosis, hepatitis C or D;
             Participants with severe steatohepatitis will be excluded (participants with
             non-alcoholic fatty liver disease [NAFLD] with steatosis only and/or mild to moderate
             steatohepatitis are acceptable)

          -  Positive anti-HIV

          -  Renal insufficiency with calculated (by MDRD method) creatinine clearance &lt;60 mL/min
             within 8 weeks prior to randomization

          -  Platelet count &lt;90,000 /mm3, hemoglobin &lt;13 g/dL (males) or &lt;12 g/dL (females),
             absolute neutrophil count &lt;1500 /mm^3 (&lt;1000/mm^3 for African-Americans) within 8
             weeks prior to randomization

          -  History of active alcohol or drug abuse within 48 weeks of screening.

          -  Pre-existing psychiatric condition(s), including but not limited to: Current moderate
             or severe depression as determined by the study physician, history of depression
             requiring hospitalization within past 10 years, history of suicidal or homicidal
             attempt within the past 10 years, or history of severe psychiatric disorders
             including but not limited to schizophrenia, psychosis, bipolar disorder

          -  History of immune-mediated disease, or cerebrovascular, chronic pulmonary or cardiac
             disease associated with functional limitation, retinopathy, uncontrolled thyroid
             disease, poorly controlled diabetes or uncontrolled seizure disorder

          -  Any medical condition that would be predicted to be exacerbated by therapy or that
             would limit study participation

          -  Any medical condition requiring or likely to require chronic systemic administration
             of corticosteroids or other immunosuppressive medications during the course of this
             study

          -  Evidence of active or suspected malignancy, or a history of malignancy within the
             last 144 weeks (except adequately treated carcinoma in situ or basal cell carcinoma
             of the skin)

          -  Need for ongoing use of any antivirals with activity against HBV during the course of
             the study

          -  Any other condition that in the opinion of the investigator would make the
             participant unsuitable for enrollment or could interfere with the participant
             participating in and completing the study.

          -  Participation in any other clinical trial involving investigational drugs within 30
             days of randomization or intention to participate in another clinical trial during
             this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Doo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle E Danielson, PhD</last_name>
    <phone>412-624-5555</phone>
    <email>danielsonm@edc.pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Pelesko, BS</last_name>
    <phone>412-383-9584</phone>
    <email>peleskoa@edc.pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tram T. Tran, MD</last_name>
      <phone>310-423-1971</phone>
      <email>tram.tran@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Han, MD</last_name>
      <phone>310-206-0645</phone>
      <email>steven.han@ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stewart Cooper, MD</last_name>
      <phone>415-600-1530</phone>
      <email>coopersl@sutterhealth.org</email>
    </contact>
    <contact_backup>
      <phone>415-600-1020</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norah Terrault</last_name>
      <phone>415-476-2227</phone>
      <email>norah.terrault@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Mandana Khalili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoky Tsai, MD</last_name>
      <phone>808-691-7609</phone>
      <email>naoky@hawaii.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Ghany, MD</last_name>
      <phone>301-402-5115</phone>
      <email>marcg@intra.niddk.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darryl Lau, MD</last_name>
      <phone>617-362-1098</phone>
      <email>dlau@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond T. Chung, MD</last_name>
      <phone>617-724-7562</phone>
      <email>rtchung@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lok, MD</last_name>
      <phone>734-936-7511</phone>
      <email>aslok@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Hassan, MD</last_name>
      <phone>612-625-8999</phone>
      <email>hassan042@umn.edu</email>
    </contact>
    <contact_backup>
      <phone>612-626-1716</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis R. Roberts, MB, ChB, PhD</last_name>
      <phone>507-538-4877</phone>
      <email>roberts.lewis@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Di Bisceglie, MD</last_name>
      <phone>314-577-8551</phone>
      <email>dibiscam@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Lisker-Melman, MD</last_name>
      <phone>314-747-3969</phone>
      <email>mlisker@dom.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael W. Fried, MD</last_name>
      <phone>919-966-2516</phone>
      <email>mfried@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew J Muir, MD</last_name>
      <phone>919-668-2673</phone>
      <email>andrew.muir@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Perrillo, MD</last_name>
      <phone>214-820-2956</phone>
      <email>roberper@baylorhealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Lee, MD</last_name>
      <phone>214-645-6110</phone>
      <email>william.lee@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23498</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Sterling, MD</last_name>
      <phone>804-828-4060</phone>
      <email>rksterli@vcu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Carithers, MD</last_name>
      <phone>206-598-4956</phone>
      <email>robertc@medicine.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia Wang, MD, MS</last_name>
      <phone>206-341-1452</phone>
      <email>chia.wang@vmmc.org</email>
    </contact>
    <contact_backup>
      <phone>206-341-1021</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Toronto-Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Janssen, MD</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>2776</phone_ext>
      <email>harry.janssen@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Jordan Feld, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David K. Wong, MD, FRCP (C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Juan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hepbnet.org/</url>
    <description>Hepatitis B Research Network</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 28, 2015</lastchanged_date>
  <firstreceived_date>June 6, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
